Senator Bill Cassidy, Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, along with several colleagues, announced on Mar. 25 an investigation into chemical abortion drug manufacturers’ compliance with U.S. Food and Drug Administration (FDA) safety requirements. The senators also called on the FDA to address illegal online sales of unapproved and misbranded chemical abortion drugs.
The senators say their actions are aimed at protecting women’s health by ensuring proper oversight of abortion drugs sold in the United States. The HELP Committee has legislative responsibility for public health issues and provides oversight for federal agencies such as the FDA according to its official website.
“Chemical abortion drug makers profit off killing innocent children while putting mothers’ lives at risk,” said Dr. Cassidy. “These manufacturers and websites have facilitated the explosion in online sales of these harmful drugs without regard for women’s health and safety while opening the door for coercion and abuse. FDA should act within its existing authorities to curb this abuse and immediately reinstate safeguards such as the in-person dispensing requirement.”
Other senators echoed concerns about online sales lacking medical supervision. Senator Steve Daines said: “There is substantial real-world evidence that shows chemical abortion is harmful to women, and it’s past time that we put commonsense safeguards in place.” Senator James Lankford added: “The FDA must enforce the law, hold manufacturers accountable and crack down on illegal distribution.”
Committee members pointed out that previous changes removed requirements like reporting non-fatal adverse events or mandating in-person dispensing for mifepristone—a move they claim led to more cases of coerced abortions or untreated complications. Questions were raised about how current manufacturers ensure compliance when pills are distributed online without direct medical oversight.
The HELP Committee plays a central role in shaping federal regulations affecting health across the country according to its official website. It oversees laws related to public health, education, workforce issues, retirement programs as reported by its official site, as well as key agencies including both FDA and National Institutes of Health according to committee information.
Representatives from advocacy groups voiced support for further scrutiny of chemical abortion drugs. Marjorie Dannenfelser said: “We are now at over 1.1 million abortions per year… Chairman Cassidy and fellow pro-life senators are boldly confronting this crisis head-on.” Carol Tobias commented: “Women deserve real medical care, not drugs dispensed through anonymous websites with little to no oversight.”
As chair during the 119th Congress according to committee records, Cassidy has led hearings on these topics before—most recently featuring Louisiana Attorney General Liz Murrill—and continues urging federal officials for stricter reviews.
Broader implications include potential changes in how chemical abortion drugs are regulated nationwide if new safeguards or enforcement actions follow from this investigation.
